# Presentation: 040744

## Vaccines and Related Biological Products Advisory Committee Meeting 

**Vaccines and Related Biological Products Advisory Committee Meeting **
**Preventive HPV Vaccine Endpoints****November 28-29, 2001****Bethesda, MD**
**Karen L. Goldenthal, M.D.**
**Division of Vaccines and **
**   ****Related Products Applications**
**US Food and Drug Administration**

## Acknowledgements

**Douglas R. Pratt, M.D., M.P.H. **
**Antonia Geber, M.D. **
**Donna K. Chandler, Ph.D. **
**Jerry P. Weir, Ph.D. **
**Gopa Raychaudhuri, Ph.D. **
**Jerry D. Willett, M.D. **
**Rebecca L. Sheets, Ph.D. **
**Robert W. Anderson, Ph.D. **
**Rakesh Pandey, Ph.D. **
**Karen Midthun, M.D. **
**Theresa M. Finn, Ph.D. **

## Cervical Cancer    Global Perspective

**Worldwide, 3rd most common CA in women********* **
**After breast and colon/rectum cancer**
**Developing countries:  2nd most common CA**
**Developed countries:  6th most common CA**
**Worldwide, ~400,000 to 500,000 new cases/yr**
**Disturbing trend, Finland:  Between 1991-95, 60% ******** in cervical CA incidence for women <55 yrs of age****#**
**Worldwide, 190,000 deaths per yr********
**~78% in developing countries**
*******Parkin DM, et al.  **_**Int J Cancer**_** 1999;80:827–41.  (Worldwide CA incidence, 1990)**
********Pisani P, et al.  **_**Int J Cancer**_** 1999;83:18–29.  (Worldwide CA mortality, 1990)**
**#****Dillner J, 2000; Anttila et al., 1999.**

## Cervical Cancer    U.S.A. Perspective

**In 1930s, cervical CA most common cause of CA deaths in U.S. women**
**Incidence/mortality rates for cervical CA declined dramatically following Pap screening & intervention**
**For 2001, ~12,900 new cases of cervical CA and 4,400 deaths due to cervical CA projected for U.S.***
**Woman's lifetime risk of cervical CA dx currently ~0.85%; risk of dying from disease is ~0.30%** **
***Janicek MF & Averette HE, 2001;  Greenlee RT et al., 2001 **
****Ries LAG et al., 2000 (Surveillance, Epidemiology, & End Results [SEER] data, NCI) **

## Precursor Lesions of Cervical Carcinoma

**From Figure 6.13, DeMay RM.  The Art and Science of Cytopathology.  CD-ROM.  ASCP.  1999.**
**Wright TC, Kurman RJ, Ferenczy A: Precancerous Lesions of the Cervix. In Kurman RJ, ed: *****Blaustein's Pathology of the Female Genital Tract.***** 4th ed. New York: Springer-Verlag NY Inc, 1994.**
**LSIL = Low Grade Squamous Intraepithelial Lesion     CIN = Cervical Intraepithelial Neoplasia**
**HSIL = High Grade Squamous Intraepithelial Lesion**

**                  ****LSIL****	****	****	****HSIL**
**	****     ****CIN 1               CIN 2****	****        ****	****	****CIN 3**
**Normal      Mild****	****        ****	****   Moderate****	****  Severe****	****Carcinoma**
**	****     ****Dysplasia       Dysplasia        Dysplasia****	*****in situ*****	**

## Above, right.  CIN 3, cervix.  Note adjacent koilocytes (bottom right).  http://hsc.virginia.edu/med-ed/path/gyn/cervix4.html

**Above, right.  CIN 3****, cervix.  ****Note adjacent koilocytes (bottom right).****  **_**http://hsc.virginia.edu/med-ed/path/gyn/cervix4.html**_

**Above, left.  Squamous carcinoma *****in situ***** (CIS), cervix.****  To the right is normal squamous epithelium with its basal cell layer & orderly maturation upwards.  The left side shows CIS characterized by lack of maturation, altered cell polarity, nuclear pleomorphism & increased nuclear / cytoplasmic ratio.   As is characteristic of CIS, neoplastic cells are confined to the epithelial layer & have not invaded through the epithelial basement membrane, under which, the submucosal stroma contains chronic inflammatory cells.  **
**Cornell Medical School  **_**http://www.pathinfo.com/alphlit.htm**_

## Cervical Lesions: “Pyramid” of Findings (U.S.)*

*******From ALTS: The ASCUS/LSIL Triage Study Newsletter, Vol 1, Issue 1**
****More recent projection: 12, 900 cases/yr for 2001**
**Janicek MF & Averette HE, 2001;  Greenlee RT et al., 2001**
** **
**ASCUS**** = Atypical Squamous Cells of Undetermined Significance.  **
**A recommendation from The Bethesda 2001 Workshop:  Replace term ASCUS with **
**ASC**** (Atypical Squamous Cells). **

**Cancer** **~15,000 cases/yr****

**HSIL **
-   **~300,000 cases/yr**

**LSIL**
**   ****~1,250,000 cases/yr**

**ASCUS **
**   ****~2,000,000 cases/yr**

## Natural History of CIN 

**Table 7 (Modified) from ****Östör**** AG: Natural history of cervical intraepithelial neoplasia:  A critical review  **_**Int. J Gynecol. Pathol.**_** 12:186-92, 1993.  (Literature Review)**

- 		**Regress****	****Persist****	****Progression to**
**	****	****	****	****	****	****CIN 3****	****   Invasion**
**  ****CIN 1****	****57%****	****	****32%****	****	****11%****	****   1%****	**
**  ****CIN 2****	****43%****	****	****35%****	****	****22%****	****   5%****	**
**  ****CIN 3****	****32%****	****	****<56%****	****	****   >12%**

## Natural History of CIN

**Limitations**** of this literature review, e.g.:*******
**Biopsy may alter natural history**
**1950s-1990; Non-uniform diagnostic criteria**
**Cytology does not always predict histology **
**“****Jigsaw puzzle effect” e.g., CIN 1 & 3 in same cervix**
**Lack of long-term follow-up**
**Estimate ****CIN 3 to ICC**** “>12%” likely too low,**** ****may be ****20-30% within 5-10 yrs********

******* ****Östör**** ****AG: **_**Int J Gynecol Pathol**_** 12:186-92, 1993.  (Lit Review)**
********Chang AR: CIS of the cervix & its malignant potential.  A lesson from New Zealand. **_**Cytopathology**_** 1:321-8, 1990. **

## Natural History of Cervical Dysplasiaa  

**Cytology    Progression****b****	****      Progression to****	****     Regression**
**	****	****	****	****      ****Invasive Cancer    to Normal****c**
**	****        ****6 mos****	****24 mos    6 mos****	****24 mos****	**
**ASCUS      2%****	****7.2%****	****      0.06%****	****0.25%****	****      68.2%****	**
**LSIL****	****        6.6%****	****20.8%****	****      0.04%****	****0.15%****	****      47.4%****	**
**HSIL****	****        6.8%****	****23.4%****	****      0.15%****	****1.44%****	****      35.0%****	**
**a****Data source:  Melnikow J et al., Natural history of cervical squamous intraepithelial lesions: a meta-analysis.  **_**Obstet Gynecol**_**  1998;92:727-735.   Also, ****from Table 3 in:  Bristow RE et al.**  **Workup of the Abnormal Pap Test.  **_**Clinical Cornerstone**_** 3:12-24, 2000.**
**b****Follow-up smears or biopsies showed a higher grade lesion than the**
**entry cytology.  For HSIL, progression to CIN 3 (from grade 2) or CIS.  ****c****Neg. result of F/U cytology or biopsy.  No relationship found between proportion of subjects regressing to normal & length of follow-up. **

## HPV Vaccine Composition 

**93% HPV positive by PCR*******
**5 most common HPV types:**
**HPV 16 in 50%****   HPV 31 in 5.3 %   HPV 33 in 2.8%**
**HPV 18 in 14%****   HPV 45 in 8.4%**
**Subsequently, 97% HPV positive with improved retesting (e.g., more sensitive primers); 99.7 % w/author-defined adequate specimens****** **
*** ****Bosch FX et al., **_**J Natl Cancer Inst**_** 1995;87:796-802. **
**** ****Walboomers, J.M.M. **_**J. Pathol**_** 1999;189:12**** ̄****19.**
**    ****Meijer C et al.: Commentary in **_**Histopathology**_** 1998;33:83-6. **

**Worldwide survey >1000 invasive cervical cancers*******

## Squamous Cell Carcinoma* - HPV 16 Most Common Type 

**HPV ****	****	****Bosch****	****Iwasawa**
**Type ****	****N=881****	****N=352**
**HPV 16****	****51%****	****	****78% **
**HPV 18****	****12%****	****	****16%**

**Bosch FX et al.  **_**JNCI**_** 87:796-802, 1995**
**Iwasawa A et al.  **_**Cancer**_** 1996;77:2275–9.**
*******Cervix**

## Adenocarcinoma (Cervix) - HPV 18 - Most Common Type

**Bosch FX et al.  **_**JNCI**_** 1995; 87:796-802.    (Global cases)**
**Iwasawa A et al.  Cancer 1996;77:2275–9.    (Finnish cases)**
**Andersson S et al.  **_**Eur J Cancer**_** 2001;37:246-50.    (Swedish cases)**
**Pirog EC et al.  **_**Am J Pathol**_** 2000;157:1055–62.    (US & Polish cases)**
** *****Excludes 6 HPV neg cases of nonmucinous adenocarcinomas (clear cell, serous & mesonephric).**

**HPV****	****      Bosch****	****  Iwasawa****	**** Andersson   Pirog Type****	****      N=25****	****  N=108****	**** N=131****	****    N=****	****67***
**HPV 16   28%****	****  17%****	****	**** 24%****	****	****    36%     **
**HPV 18   56%****	****  56%****	****	**** 37%****	****	****    36%**

## Incidence of Squamous Cell Carcinoma (SCC) vs. Adenocarcinoma (ADC) of the Cervix 

**Cytology screening - far less impact on incidence of ADC compared to SCC***
**In U.S., review of SEER database has shown **
**A clear **_**decrease**_** in incidence of SCC, and invasive cervical cancer (ICC) overall; **
**However, an **_**increase**_** in the rate of ADC**
**Overall, similar findings in Scandinavia**

***Smith HO, et al.  The rising incidence of adenocarcinoma relative to **
**squamous cell carcinoma of the uterine cervix in the U.S.--a 24-year **
**population-based study.  **_**Gynecol Oncol**_** 2000;78:97-105.**

## Risk of CIN 2 or 3: Relation to HPV Type 16 and 18

**241 women presenting for ****STD evaluation**** & with ****negative**** cervical cytology***
**Followed q4 months (ave. F/U 25 mos): **
**Cytology, **_**colposcopy**_**, HPV DNA, STDs**
**CIN 2 or 3 (biopsy) in 28 women (11.6%)**
**If ****+ HPV type 16 or 18,**** ****adj. RR 11**** (4.6-26) for CIN 2 or 3 compared to those w/o HPV**
**Attributable proportion to types 16 & 18 = 52% **
**Only 36% (10/28) had LSIL Pap before HSIL Pap**
**Subset HPV DNA neg. on 1****st**** 2 visits **
**In subsequent 2 yrs, 8.6% (9/105)** had CIN 2/3 dx**

***Koutsky L, et al.: A cohort study of the risk of CIN 2 or 3 in relation to papillomavirus infection.  **_**NEJM**_** 327:1272-8, 1992.  (STD clinic, Seattle, WA)**
****8 of 9 cases occurred among 35 women who developed HPV infection**

## Risk of CIN 2 or 3: Relation to HPV Type 16

**1075 women with normal cytology **_**and**_** HPV negative tests at baseline***
**Followed q6 months: Pap smear & HPV DNA (median FU = 26 months)**
**If abn. cytology, referred to colposcopy/bx**
**CIN 2 or 3 (biopsy) in 28 women**** (2.6%)**
**Median time to dx = 36 months from study entry**
**20 of these CIN 2/3 cases diagnosed during work-up of the 1****st**** episode of abn. cytology**
**If ****+ HPV type 16,**** ****adj. RR 8.5**** (3.7 to 19) for CIN 2 or 3 compared to those w/o HPV**

***Woodman CB, et al.  Natural history of cervical human papillomavirus infection **
**in young women: a longitudinal cohort study.  **_**Lancet**_** 2001;357:1831–36.**

## Stages of Review and Regulation

**Clinical Investigational Plan**

**Phase 1**
**Safety**
**Immuno-**
**genicity**

**Phase 2**
**Immuno-genicity**
**Safety**
**Dose Ranging**

**Phase 3**
**Efficacy**
**Safety**
**Immuno-genicity**

**BLA**
**Data to support approval;**
**Inspection**

**Phase 4**
**Inspection**
**Safety**
**Efficacy**
**Lot Release**

**BLA Supplement**
**Post-approval**
**Changes:**
**New Indications**
**Dosing**
**Manufacture**
**Equipment/**
**Facilities**

-                **IND**

**IND = Investigational New Drug Application;  **
**BLA = Biologics License Application**

## “Theoretical” Endpoints - HPV Preventive Vaccines

**Types 16, 18 and other “high risk” types**
**Virology (various definitions of incident or persistent infection)**
**LSIL cytology (w/o biopsy confirmation) or worse with virology**
**CIN 1 histology, AIS*, or worse with virology (Hereafter = CIN 1 or worse**** ****with virology)**
**CIN 2/3 histology, AIS, or worse with virology (Hereafter = CIN 2/3 or worse**** ****w/virology)**
**Invasive cervical cancer with or w/o virology**

***AIS = Adenocarcinoma *****in situ *****(of the cervix)**

## Possible Endpoints – HPV Vaccines

**Virology (only)**** - *****Advantages***
**Feasibility**
**Smaller Trial, i.e., a few thousand**
**Populations exist in many countries w/sufficient incident HPV “infection” rate, e.g., for Type 16**** **
**U.K. - 10.5% cum for 3 yrs (Woodman CB et al., 2001)**
**U.S. - 7% cum for 2 yrs (Ho GYF et al., 1998)**
**U.S. - 4.7 / 100 person yrs (Thomas KK et al., 2000)**
**Brazil - 1.68 / 100 person yrs (Franco EL et al., 1999)**

## Possible Endpoints – HPV Vaccines

**Virology (only)**** - *****Advantages***
**HPV strongly associated with HSIL cytology, CIS and cervical cancer***
**Determine vaccine versus non-vaccine serotypes**
**Might be able to determine immune correlate**

***Koutsky LA, et al.  **_**N Engl J Med**_** 1992;327:1272-8. (CIN 2/3 and HPV infection)**
**Woodman CBJ, et al.  **_**Lancet**_** 2001;357:1831–36. (CIN 2/3 and HPV infection)**
**Ylitalo N, et al.  **_**Lancet**_** 2000;355:2194-8.  (HPV Viral load and CIS)**
**Josefsson AM, et al.  **_**Lancet**_** 355:2189, 2000.  (HPV Viral load and CIS)**
**Ylitalo N, et al.  **_**Cancer Res**_** 2000;60:6027-32.  (Long term HPV  infection and CIS)**
**Bosch FX, et al.  **_**J Natl Cancer Inst**_** 1995; 87:796-802.  (HPV and cervical cancer)**

## Possible Endpoints - HPV Vaccines

**Virology (only)**** - *****Disadvantages***
**HPV infection is not a clinical disease**
**Most HPV infection resolves**
**Durability of protection uncertain **
**? Change in lifetime risk for HSIL histology/cancer**
**Not as proximal to cancer as other endpoints**
**e.g.,**** ****may overestimate vaccine efficacy with regard to high grade lesions/cancer**
**May want definitive high grade clinical endpoint data before extensive deployment of a new HPV vaccine**** **

## Possible Endpoints - HPV Vaccines

**Virology (only)**** - *****Disadvantages***
**Uncertainty in existence of, or detection of latent infections in the cervix**
**Detection in superficial vs. basal layer cells?**
**Could a vaccine-induced immune response make HPV DNA more difficult to detect?**
**Uncertainty distinguishing new infection from re-infection (although this problem would tend to negatively bias efficacy estimate)**
**Various definitions of persistent infection, e.g., infection X 2 at 4, 6 or 12 months, not validated in previous clinical trials **

## Possible Endpoints - HPV Vaccines

**Virology (only)**** - *****Disadvantages***
**May not identify unanticipated vaccine-associated problems with virology endpoint: **
**Alteration in HPV natural history, difficulty in detecting cervical dysplasia, enhanced disease (dysplasia, cancer)**
**Post-approval, could be difficult to detect outside context of a randomized, well-controlled trial **
**Small efficacy trial **
**Provides less well-controlled safety data **
**Could be addressed w/supplemental trials**

## Possible Endpoints - HPV Vaccines

**LSIL cytology or worse w/Virology **** - *****Advantages***
**Feasibility**
**Smaller trial, i.e., a few thousand**
**LSIL leads to many clinical work-ups in developed countries**

## Possible Endpoints - HPV Vaccines

**LSIL cytology or worse w/Virology**** - *****Disadvantages***
**Clinical relevance: About half of LSIL resolves w/o therapy **
**LSIL cytology, by itself, does not represent a definitive diagnosis **
**Need histologic diagnosis for therapy**
**Without colposcopy and biopsy, if needed, cannot R/O higher grade lesions **
**CIN 2/3 found at work-up in a % of LSIL cases, even w/o prior hx of cervical disease **

## Possible Endpoints - HPV Vaccines

**LSIL cytology or worse w/ Virology**** -  *****Disadvantages (cont.)***
**Not as proximal to cancer as other endpoints**
**May want definitive high grade clinical endpoint data before extensive deployment of a new HPV vaccine **
**May be easier to identify unanticipated vaccine-associated problems with high grade disease endpoint (see earlier slide)**
**Small efficacy trial**** **
**Provides less well-controlled safety data **
**Could be addressed w/supplemental trials**

## Possible Endpoints - HPV Vaccines

**CIN 1* or worse w/ Virology**** - *****Assumptions***
**CIN 1 (biopsy) or worse (CIN 1 +) = 1****0**** endpoint**
**Virology used to classify CIN 1 + cases as vaccine serotype or not**
**Prespecify HPV testing on cervical samples vs histology to classify cases**** **
**Cases would be identified from colposcopic work-up of (mostly) ASCUS & LSIL cytology**
**Plan/algorithm for colposcopy will affect # of endpoints (more frequent = more endpoints)**
**Can’t use economics as basis for US licensure**
** ********* Histology**

## Possible Endpoints - HPV Vaccines

**CIN 1 histology or worse w/ Virology**** - *****Advantages***
**Feasibility**
**Smaller trial, i.e., a few thousand**
**Populations exist in many countries with sufficient incident CIN 1  **
**Necessitates definite work-up **
**Generates histologic dx that guides therapy**
**Data are available on the natural history of CIN 1 from initial diagnosis**

## Possible Endpoints - HPV Vaccines

**CIN 1 histology or worse w/Virology**** - *****Disadvantages***
**At least half of CIN 1 resolves w/o therapy**
**Not as proximal to cancer as other endpoints**
**May want definitive high grade clinical endpoint data before extensive deployment of a new HPV vaccine **

## Possible Endpoints - HPV Vaccines

** ****CIN 1 histology or worse w/Virology**** - *****Disadvantages (cont.)***
**May be easier to identify unanticipated vaccine-associated problems with high grade disease endpoint (see earlier slide)**
**Small efficacy trial **
**Provides less well-controlled safety data **
**Could be addressed w/supplemental trials**

## Possible Endpoints - HPV Vaccines

**CIN 2/3 or worse w/ Virology**** - *****Assumptions***
**Virology used to classify CIN 2/3 + cases as vaccine serotype or not**
**Prespecify HPV testing on cervical samples vs histology to classify cases **
**Many/most CIN 2/3 + cases would be identified from colposcopic work-up of ASCUS and LSIL********* **
**Plan/algorithm for colposcopy critical to # of endpoints (more frequent = more endpoints)**
**Many/most CIN 2/3+ cases could be those found at 1st work-up of abnormal cytology**

******* Lonky NM, et al.  The clinical significance of the poor correlation of cervical dysplasia & cervical malignancy with referral cytologic results.   **_**Am J Obstet Gynecol**_** 1999;181:560-6.**

## Possible Endpoints - HPV Vaccines

**CIN 2/3 histology or worse w/Virology**** - *****Advantages***
**More proximal to cervical cancer**** **
**Provides definitive high grade clinical endpoint data before, before wide-spread public health use****  **
**Natural history data - Prevent lesions that need therapy (US standard of care)**

## Possible Endpoints - HPV Vaccines

**CIN 2/3 histology or worse w/Virology**** - *****Advantages (cont.)***
**May be easier to identify unanticipated vaccine-associated problems with high grade disease endpoint (see earlier slide)**
**Larger efficacy trial **
**Implications for randomized safety database**

## Possible Endpoints - HPV Vaccines

**CIN 2/3 or worse w/Virology**** - *****Disadvantages***
**Feasibility - Subject #s may not differ from most vaccine efficacy trials; however, type of follow-up likely to be more resource intensive**
**Uncertainty trial size/ duration estimate??**
**Little natural hx data to est. trial size: women w/ baseline neg. HPV, normal cytology **
**12,000 women, randomized 1:1 (vaccine to placebo), vaccine efficacy **_**>**_** 80%, 3 1/2 yrs*******

- *** Preliminary estimate based on data from: **
**Woodman CBJ, et al.  **_**Lancet**_** 2001;357:1831–36.**

## Possible Endpoints - HPV Vaccines

**Cervical Cancer w or w/o Virology**** - *****Assumptions***
**One scenario (developed country)**
**Randomize subjects; infrastructure in place for routine F/U & a method of capturing all diagnoses for an area, e.g., cancer registry and death certificates**
**Scandinavian Countries ****(Comprehensive CA registries)**
**HPV testing:  Presence or absence of baseline testing before randomization, & cervical sample/ histology testing will affect efficacy level assessment**
**Esp. in U.S., many/most cervical CA cases identified from colposcopic work-up of ASC, AGC and LSIL********* **

******* Lonky NM, et al.  The clinical significance of the poor correlation of cervical dysplasia & cervical malignancy with referral cytologic results.   **_**Am J Obstet Gynecol**_** 1999;181:560-6.**

## Possible Endpoints - HPV Vaccines

**Cervical Cancer with or w/o Virology**** - *****Advantages***
**The major concern **_**is**_** cervical CA**
**Provides definitive high grade clinical endpoint data before, before wide-spread public health use  **
**May be easier to identify unanticipated vaccine-associated problems with high grade disease endpoint (see earlier slide)**

## Possible Endpoints - HPV Vaccines

**Cervical Cancer with or w/o Virology**** - *****Advantages (cont.)***
**Give best understanding of impact of vaccine (if Type 18 included) on ****adenocarcinoma**
**Larger efficacy trial**
**Implications for randomized safety database, although detailed data not expected**

## Possible Endpoints - HPV Vaccines

**Cervical Cancer with or w/o Virology**** - *****Disadvantages***
**Feasibility**
**Uncertainty **
**Trial size/ duration estimate/ population selection/countries w/o screening program??**

## Efficacy Trial Analysis

**Statistical section of protocol ****(prospective)**
**Detailed, especially for 1****o**** endpoint**
**Interim analysis**
**Intent-to-treat**** vs. per protocol: vaccine serotypes**
**Handling of mixed infections****, esp. vaccine & non-vaccine types, in ****1****o**** endpoint analysis**
**Evidence of**** ****overall benefit**** when all endpoints, including ones attributed to non-vaccine high risk HPV types, are included in an analysis**

## Accelerated Approval (AA)

**21 CFR 601.40s Subpart E: Accelerated Approval of New Biologic Products for Serious or Life-Threatening Illnesses*******
**“...****provide ****meaningful therapeutic benefit**** to patients over existing treatments (e.g., ability to treat patients unresponsive to, or intolerant of, available therapy, or improved patient response over available therapy).”**

*****_** Federal Register**_** 57;58942-60, 1992.**
**See 21 CFR 314.500s Subpart H for AA of new drugs **

## Accelerated Approval (AA)

**“****FDA may grant marketing approval for a biological product on the basis of ****adequate and well-controlled clinical trials**** establishing that a biological product has an effect on a surrogate endpoint that is reasonably likely, based on epidemiologic, therapeutic, pathophysiologic, or other evidence, to predict clinical benefit, or on the basis of an effect on a clinical endpoint other than survival or irreversible morbidity.”**** **

## Accelerated Approval (AA)

**Intended to make available promising therapies while definitive confirmatory efficacy studies being completed **
**Confirmatory post-marketing studies:**
**Usually well underway at time of AA**
**Must be adequate and well-controlled**** **
**Must be carried out with due diligence **
**Original, and current, intent of AA regulation = serve best interests of public **
**Preventive vaccines have not been previously approved using AA regulation**

## FDA Questions 

**1.****	****Please discuss and identify the most appropriate endpoints for traditional approval of HPV vaccines intended to prevent cervical cancer: **
**	****In particular, please discuss the use of the following endpoints in clinical trials intended to demonstrate the efficacy of HPV vaccines for oncogenic types, and the indications (e.g., prevention of HPV infection, etc.) these endpoints would support: **
**a.****	****Incident HPV infection by oncogenic HPV types **
**(i.e., at least one positive HPV DNA test result).**
**b.****	****Persistent HPV infection by oncogenic HPV types.**
**	****- Regarding this endpoint, please also discuss the appropriate number of positive virologic results, and the interval between positive virologic results.**
**c.  ****	****LSIL (cytology), associated w/oncogenic HPV types.**
**d.  ****	****CIN 1, associated with oncogenic HPV types.**
**e.  ****	****CIN 2/3, associated with oncogenic HPV types.**
**Cervical cancer. **

## FDA Questions (continued)

**2.****	****Please discuss the use of the accelerated approval regulations for licensure of HPV vaccines for the prevention of cervical cancer: **
**	****Specifically, please discuss and identify possible surrogate endpoints to support accelerated approval.  In particular, consider the following endpoints:**
**	****a. Incident HPV infection by oncogenic HPV types. **
**	****b. Persistent HPV infection by oncogenic HPV  types. **
**	****c. LSIL (cytology), associated w/oncogenic HPV types.**
**	****d. CIN 1, associated with oncogenic HPV types.**
**	**
**	****In the context of accelerated approval, please discuss and identify possible endpoints for the confirmatory trial.**